BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 25583329)

  • 1. Motor neuron cell-nonautonomous rescue of spinal muscular atrophy phenotypes in mild and severe transgenic mouse models.
    Hua Y; Liu YH; Sahashi K; Rigo F; Bennett CF; Krainer AR
    Genes Dev; 2015 Feb; 29(3):288-97. PubMed ID: 25583329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
    Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment.
    Sintusek P; Catapano F; Angkathunkayul N; Marrosu E; Parson SH; Morgan JE; Muntoni F; Zhou H
    PLoS One; 2016; 11(5):e0155032. PubMed ID: 27163330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A large animal model of spinal muscular atrophy and correction of phenotype.
    Duque SI; Arnold WD; Odermatt P; Li X; Porensky PN; Schmelzer L; Meyer K; Kolb SJ; Schümperli D; Kaspar BK; Burghes AH
    Ann Neurol; 2015 Mar; 77(3):399-414. PubMed ID: 25516063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-Based Therapy for Spinal Muscular Atrophy.
    Han F; Ebrahimi-Barough S; Abolghasemi R; Ai J; Liu Y
    Adv Exp Med Biol; 2020; 1266():117-125. PubMed ID: 33105498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.
    Zhou H; Meng J; Malerba A; Catapano F; Sintusek P; Jarmin S; Feng L; Lu-Nguyen N; Sun L; Mariot V; Dumonceaux J; Morgan JE; Gissen P; Dickson G; Muntoni F
    J Cachexia Sarcopenia Muscle; 2020 Jun; 11(3):768-782. PubMed ID: 32031328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
    Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
    Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
    Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy.
    Wang ZB; Zhang X; Li XJ
    Cell Res; 2013 Mar; 23(3):378-93. PubMed ID: 23208423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
    Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
    J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild SMN missense alleles are only functional in the presence of SMN2 in mammals.
    Iyer CC; Corlett KM; Massoni-Laporte A; Duque SI; Madabusi N; Tisdale S; McGovern VL; Le TT; Zaworski PG; Arnold WD; Pellizzoni L; Burghes AHM
    Hum Mol Genet; 2018 Oct; 27(19):3404-3416. PubMed ID: 29982416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies for spinal muscular atrophy: SMN and beyond.
    Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K;
    Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of neuromuscular synaptic phenotypes without enhanced survival and motor function in severe spinal muscular atrophy mice selectively rescued in motor neurons.
    Paez-Colasante X; Seaberg B; Martinez TL; Kong L; Sumner CJ; Rimer M
    PLoS One; 2013; 8(9):e75866. PubMed ID: 24086650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival motor neuron protein in motor neurons determines synaptic integrity in spinal muscular atrophy.
    Martinez TL; Kong L; Wang X; Osborne MA; Crowder ME; Van Meerbeke JP; Xu X; Davis C; Wooley J; Goldhamer DJ; Lutz CM; Rich MM; Sumner CJ
    J Neurosci; 2012 Jun; 32(25):8703-15. PubMed ID: 22723710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
    Arnold WD; Duque S; Iyer CC; Zaworski P; McGovern VL; Taylor SJ; von Herrmann KM; Kobayashi DT; Chen KS; Kolb SJ; Paushkin SV; Burghes AH
    PLoS One; 2016; 11(12):e0167077. PubMed ID: 27907033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy.
    d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ
    Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of human survival motor neuron (SMN) protein in mice containing the SMN2 transgene: applicability to preclinical therapy development for spinal muscular atrophy.
    Mattis VB; Butchbach ME; Lorson CL
    J Neurosci Methods; 2008 Oct; 175(1):36-43. PubMed ID: 18771690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy.
    Reilly A; Deguise MO; Beauvais A; Yaworski R; Thebault S; Tessier DR; Tabard-Cossa V; Hensel N; Schneider BL; Kothary R
    Gene Ther; 2022 Sep; 29(9):544-554. PubMed ID: 35462564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response.
    Zhou H; Meng J; Marrosu E; Janghra N; Morgan J; Muntoni F
    Hum Mol Genet; 2015 Nov; 24(22):6265-77. PubMed ID: 26264577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.